These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 9568550

  • 1. Modulation of the immune response of Balb/c mice against Leishmania major by imuvert.
    Taha SM, Tabbara KS.
    Int J Immunopharmacol; 1997 Aug; 19(8):443-9. PubMed ID: 9568550
    [Abstract] [Full Text] [Related]

  • 2. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
    Badiee A, Jaafari MR, Khamesipour A.
    Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
    [Abstract] [Full Text] [Related]

  • 3. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S.
    Vaccine; 2004 May 07; 22(15-16):1930-40. PubMed ID: 15121305
    [Abstract] [Full Text] [Related]

  • 4. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F, Di Roberto RB, Gillard J, Cousineau B.
    Vaccine; 2012 Aug 24; 30(39):5726-32. PubMed ID: 22814408
    [Abstract] [Full Text] [Related]

  • 5. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
    Méndez S, Gurunathan S, Kamhawi S, Belkaid Y, Moga MA, Skeiky YA, Campos-Neto A, Reed S, Seder RA, Sacks D.
    J Immunol; 2001 Apr 15; 166(8):5122-8. PubMed ID: 11290794
    [Abstract] [Full Text] [Related]

  • 6. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
    Salay G, Dorta ML, Santos NM, Mortara RA, Brodskyn C, Oliveira CI, Barbiéri CL, Rodrigues MM.
    Clin Vaccine Immunol; 2007 Sep 15; 14(9):1173-81. PubMed ID: 17626159
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S.
    Exp Parasitol; 2011 Mar 15; 127(3):627-36. PubMed ID: 21187087
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Co-administration of rectal BCG and autoclaved Leishmania major induce protection in susceptible BALB/c mice.
    Soudi S, Hosseini AZ, Hashemi SM.
    Parasite Immunol; 2011 Oct 15; 33(10):561-71. PubMed ID: 21781137
    [Abstract] [Full Text] [Related]

  • 11. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase.
    Rafati S, Baba AA, Bakhshayesh M, Vafa M.
    Clin Exp Immunol; 2000 Apr 15; 120(1):134-8. PubMed ID: 10759774
    [Abstract] [Full Text] [Related]

  • 12. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA.
    J Exp Med; 1997 Oct 06; 186(7):1137-47. PubMed ID: 9314562
    [Abstract] [Full Text] [Related]

  • 13. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK, Mbati PA, Anjili CO, Orago AS, Turco SJ, Githure JI, Koech DK.
    East Afr Med J; 2001 Feb 06; 78(2):90-2. PubMed ID: 11682953
    [Abstract] [Full Text] [Related]

  • 14. Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection.
    Cargnelutti DE, Salomón MC, Celedon V, García Bustos MF, Morea G, Cuello-Carrión FD, Scodeller EA.
    J Microbiol Immunol Infect; 2016 Feb 06; 49(1):24-32. PubMed ID: 24662018
    [Abstract] [Full Text] [Related]

  • 15. Intravenous injection of irradiated Leishmania major into susceptible BALB/c mice: immunization or protective tolerance.
    Aebischer T, Morris L, Handman E.
    Int Immunol; 1994 Oct 06; 6(10):1535-43. PubMed ID: 7826944
    [Abstract] [Full Text] [Related]

  • 16. Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection.
    Liew FY, Hale C, Howard JG.
    J Immunol; 1985 Sep 06; 135(3):2095-101. PubMed ID: 4020140
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
    Li J, Nolan TJ, Farrell JP.
    Exp Parasitol; 1997 Sep 06; 87(1):47-57. PubMed ID: 9287957
    [Abstract] [Full Text] [Related]

  • 19. Vaccinations with live-attenuated Leishmania major promastigotes and challenge infection with L. major in BALB/c mice.
    Onyalo JA, Mwala DM, Anjili CO, Orago AS, Tonui WK.
    East Afr Med J; 2005 Apr 06; 82(4):193-7. PubMed ID: 16122087
    [Abstract] [Full Text] [Related]

  • 20. Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis.
    Eskandari F, Talesh GA, Parooie M, Jaafari MR, Khamesipour A, Saberi Z, Abbasi A, Badiee A.
    Exp Parasitol; 2014 Nov 06; 146():78-86. PubMed ID: 25246326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.